Cargando…
Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury
INTRODUCTION: This study tested the hypothesis that cyclosporine (CsA)-supported syngeneic adipose-derived mesenchymal stem cell (ADMSC) therapy offered superior attenuation of acute ischemia–reperfusion (IR) kidney injury to either therapy alone. METHODS: Adult Sprague–Dawley rats (n = 40) were equ...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706768/ https://www.ncbi.nlm.nih.gov/pubmed/23726287 http://dx.doi.org/10.1186/scrt212 |
_version_ | 1782276401779441664 |
---|---|
author | Chen, Yen-Ta Yang, Chih-Chau Zhen, Yen-Yi Wallace, Christopher Glenn Yang, Jenq-Lin Sun, Cheuk-Kwan Tsai, Tzu-Hsien Sheu, Jiunn-Jye Chua, Sarah Chang, Chia-Lo Cho, Chung-Lung Leu, Steve Yip, Hon-Kan |
author_facet | Chen, Yen-Ta Yang, Chih-Chau Zhen, Yen-Yi Wallace, Christopher Glenn Yang, Jenq-Lin Sun, Cheuk-Kwan Tsai, Tzu-Hsien Sheu, Jiunn-Jye Chua, Sarah Chang, Chia-Lo Cho, Chung-Lung Leu, Steve Yip, Hon-Kan |
author_sort | Chen, Yen-Ta |
collection | PubMed |
description | INTRODUCTION: This study tested the hypothesis that cyclosporine (CsA)-supported syngeneic adipose-derived mesenchymal stem cell (ADMSC) therapy offered superior attenuation of acute ischemia–reperfusion (IR) kidney injury to either therapy alone. METHODS: Adult Sprague–Dawley rats (n = 40) were equally divided into group 1 (sham controls), group 2 (IR injury), group 3 (IR + CsA (20 mg/kg at 1 and 24 hours after procedure)), group 4 (syngeneic ADMSC (1.2×10(6)) at 1, 6 and 24 hours after procedure), and group 5 (IR + CsA-ADMSC). RESULTS: By 72 hours after the IR procedure, the creatinine level and the ratio of urine protein to creatinine were highest in group 2 and lowest in group 1, and significantly higher in groups 3 and 4 than in group 5 (all P <0.05 for inter-group comparisons), but showed no differences between groups 3 and 4 (P >0.05). The inflammatory biomarkers at mRNA (matrix metalloproteinase-9, RANTES, TNF-α), protein (TNF-α, NF-κB, intercellular adhesion molecule-1, platelet-derived growth factor), and cellular (CD68(+)) levels of IR kidney showed a similar pattern compared with that of creatinine in all groups (all P <0.05 for inter-group comparisons). The protein expressions of oxidative stress (oxidized protein), reactive oxygen species (NADPH oxidases NOX-1, NOX-2), apoptosis (Bcl-2–associated X protein, caspase-3 and poly(ADP-ribose) polymerase) and DNA damage (phosphorylated H2A histone family member X-positive, proliferating cell nuclear antigen-positive cells) markers exhibited a pattern similar to that of inflammatory mediators amongst all groups (all P <0.05 for inter-group comparisons). Expressions of antioxidant biomarkers at cellular (glutathione peroxidase, glutathione reductase, heme oxygenase-1 (HO-1)) and protein (NADPH dehydrogenase (quinone)-1, HO-1, endothelial nitric oxide synthase) levels, and endothelial progenitor cell markers (C-X-C chemokine receptor type 4-positive, stromal cell-derived factor-1α-positive) were lowest in groups 1 and 2, higher in groups 3 and 4, and highest in group 5 (all P <0.05 for inter-group comparisons). CONCLUSION: Combination therapy using CsA plus ADMSCs offers improved protection against acute IR kidney injury. |
format | Online Article Text |
id | pubmed-3706768 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37067682013-07-15 Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury Chen, Yen-Ta Yang, Chih-Chau Zhen, Yen-Yi Wallace, Christopher Glenn Yang, Jenq-Lin Sun, Cheuk-Kwan Tsai, Tzu-Hsien Sheu, Jiunn-Jye Chua, Sarah Chang, Chia-Lo Cho, Chung-Lung Leu, Steve Yip, Hon-Kan Stem Cell Res Ther Research INTRODUCTION: This study tested the hypothesis that cyclosporine (CsA)-supported syngeneic adipose-derived mesenchymal stem cell (ADMSC) therapy offered superior attenuation of acute ischemia–reperfusion (IR) kidney injury to either therapy alone. METHODS: Adult Sprague–Dawley rats (n = 40) were equally divided into group 1 (sham controls), group 2 (IR injury), group 3 (IR + CsA (20 mg/kg at 1 and 24 hours after procedure)), group 4 (syngeneic ADMSC (1.2×10(6)) at 1, 6 and 24 hours after procedure), and group 5 (IR + CsA-ADMSC). RESULTS: By 72 hours after the IR procedure, the creatinine level and the ratio of urine protein to creatinine were highest in group 2 and lowest in group 1, and significantly higher in groups 3 and 4 than in group 5 (all P <0.05 for inter-group comparisons), but showed no differences between groups 3 and 4 (P >0.05). The inflammatory biomarkers at mRNA (matrix metalloproteinase-9, RANTES, TNF-α), protein (TNF-α, NF-κB, intercellular adhesion molecule-1, platelet-derived growth factor), and cellular (CD68(+)) levels of IR kidney showed a similar pattern compared with that of creatinine in all groups (all P <0.05 for inter-group comparisons). The protein expressions of oxidative stress (oxidized protein), reactive oxygen species (NADPH oxidases NOX-1, NOX-2), apoptosis (Bcl-2–associated X protein, caspase-3 and poly(ADP-ribose) polymerase) and DNA damage (phosphorylated H2A histone family member X-positive, proliferating cell nuclear antigen-positive cells) markers exhibited a pattern similar to that of inflammatory mediators amongst all groups (all P <0.05 for inter-group comparisons). Expressions of antioxidant biomarkers at cellular (glutathione peroxidase, glutathione reductase, heme oxygenase-1 (HO-1)) and protein (NADPH dehydrogenase (quinone)-1, HO-1, endothelial nitric oxide synthase) levels, and endothelial progenitor cell markers (C-X-C chemokine receptor type 4-positive, stromal cell-derived factor-1α-positive) were lowest in groups 1 and 2, higher in groups 3 and 4, and highest in group 5 (all P <0.05 for inter-group comparisons). CONCLUSION: Combination therapy using CsA plus ADMSCs offers improved protection against acute IR kidney injury. BioMed Central 2013-05-31 /pmc/articles/PMC3706768/ /pubmed/23726287 http://dx.doi.org/10.1186/scrt212 Text en Copyright © 2013 Chen et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Chen, Yen-Ta Yang, Chih-Chau Zhen, Yen-Yi Wallace, Christopher Glenn Yang, Jenq-Lin Sun, Cheuk-Kwan Tsai, Tzu-Hsien Sheu, Jiunn-Jye Chua, Sarah Chang, Chia-Lo Cho, Chung-Lung Leu, Steve Yip, Hon-Kan Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury |
title | Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury |
title_full | Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury |
title_fullStr | Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury |
title_full_unstemmed | Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury |
title_short | Cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury |
title_sort | cyclosporine-assisted adipose-derived mesenchymal stem cell therapy to mitigate acute kidney ischemia–reperfusion injury |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706768/ https://www.ncbi.nlm.nih.gov/pubmed/23726287 http://dx.doi.org/10.1186/scrt212 |
work_keys_str_mv | AT chenyenta cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT yangchihchau cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT zhenyenyi cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT wallacechristopherglenn cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT yangjenqlin cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT suncheukkwan cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT tsaitzuhsien cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT sheujiunnjye cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT chuasarah cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT changchialo cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT chochunglung cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT leusteve cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury AT yiphonkan cyclosporineassistedadiposederivedmesenchymalstemcelltherapytomitigateacutekidneyischemiareperfusioninjury |